by CCH Admin | Mar 3, 2021 | Sponsors
Started: 8/2018 Study Name: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of XXX Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 years and older) with Molluscum Contagiosum Indication:...
by CCH Admin | Mar 3, 2021 | Sponsors
Started: 6/2018 Study Name: A Phase 2, Open Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of XXX Topical Film Forming Solution [0.7% (w/v) cantharidin] in Subjects (2 years and older) with Molluscum Contagiosum. Indication: Molluscum Principal...
by CCH Admin | Mar 3, 2021 | Sponsors
Started: 11/2018 Study Name: CP40559 – A Multicenter, Single-Arm, Open-Label Study To Assess The Safety, Pharmacokinetics, And Efficacy Of XXX In Otherwise Healthy Pediatric Patients From Birth To <1 Year With Influenza-Like Symptoms Indication: Influenza...
by CCH Admin | Mar 3, 2021 | Sponsors
Started: 11/2018 Study Name: CP40563 – A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study To Assess The Safety, Pharmacokinetics, And Efficacy Of XXX In Otherwise Healthy Pediatric Patients 1 to <12 Years Of Age With Influenza-Like...
by CCH Admin | Mar 3, 2021 | Sponsors
Started: 10/2017 Study Name: A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants. Indication: RSV...
by CCH Admin | Mar 3, 2021 | Sponsors
Started: 10/2017 Study Name: XXX liquid formulation of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (XXX) HRV vaccine (Rotarix®, GSK Biologicals) Indication: ROTA Virus Principal Investigators: Luke Anschutz, Paul Bernhardson,...
